(Q33338157)

25 July 2017

title

A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3). (English)

1 reference

non-small-cell lung carcinoma

25 July 2017

main subject

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

D Rinaldi

1

1 reference

25 July 2017

N Lormand

2

1 reference

25 July 2017

J Brierre

3

1 reference

25 July 2017

J Cole

4

1 reference

25 July 2017

B Barnes

5

1 reference

25 July 2017

F Fontenot

6

1 reference

25 July 2017

E Buller

7

1 reference

25 July 2017

J Rainey

8

1 reference

25 July 2017

publication date

1 January 2001

1 reference

25 July 2017

1 reference

25 July 2017

volume

19

1 reference

25 July 2017

issue

5

1 reference

25 July 2017

page(s)

467-474

1 reference

Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100103845

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100103845

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100103845

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-100103845

21 January 2018

Identifiers

DOI

10.1081/CNV-100103845

1 reference

25 July 2017

1 reference